anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech)
Drug Alias NameLCAR-AMDR CLL-1/CD33 cells (Nanjing Legend Biotech)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A